deferasirox has been researched along with Bronze Diabetes in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilar Hinojosa, NK; Figueroa Saavedra, EI | 1 |
| Lee, JA; Tchantchaleishvili, V; Vidula, H | 1 |
| Bardou-Jacquet, E; Beaumont-Epinette, MP; Ben Ali, Z; Brissot, P; Jouanolle, AM; Loreal, O | 1 |
| Baer, J; Brewer, C; Garner, M; Stadler, CK; Tyszka, JM; Wood, JC | 1 |
| Ballas, SK; Cançado, R; Chiattone, C; de Moraes Bastos, R; Guerra-Shinohara, EM; Melo, MR; Santos, PC | 1 |
| Allegra, S; Arduino, A; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E | 1 |
| Cho, HS; Kang, JI; Kim, DM; Kim, HS; Park, CY | 1 |
| Allegrini, PR; Fozard, L; Junker, U; Nick, H; Niederkofler, V; O'Reilly, T; Rojkjaer, L; Salie, R | 1 |
| Aslam, N; Marsano-Obando, LS; Martin, A; Mettu, P | 1 |
| Adams, PC; Bonkovsky, HL; Brissot, P; Griffel, L; Gross, J; Lynch, N; Malfertheiner, P; McLaren, GD; Niederau, C; Phatak, P; Pietrangelo, A; Piperno, A; Powell, LW; Russo, MW; Stoelzel, U; Stremmel, W; Wurster, M; Zhang, Y | 1 |
| Cançado, RD; Chiattone, CS; Guerra-Shinohara, EM; Krieger, JE; Pereira, AC; Santos, PC | 1 |
| Melpignano, A; Quarta, A; Quarta, G | 1 |
| Gregor, M; Nagler, M; Wuillemin, WA | 1 |
| Ariizumi, H; Hattori, A; Hayashi, H; Maeda, T; Nakamaki, T; Nakashima, H; Saito, B; Suzuki, K; Tatsumi, Y; Tomoyasu, S; Yanagisawa, K | 1 |
| Imran, FS; Phatak, P | 1 |
| Hayashi, H; Maeda, H; Naoe, T; Ohashi, H; Saito, H; Tomita, A | 1 |
| Chen, YM; Huang, CC; Kuo, CC; Tsai, CW; Yang, FJ | 1 |
| Maekawa, T; Yoshioka, S | 1 |
| Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ | 1 |
| Niederau, C | 1 |
| Kontoghiorghes, GJ | 1 |
| Barton, JC | 1 |
| Brissot, P; Deugnier, Y; Loréal, O | 1 |
| Bardou-Jacquet, E; Brissot, P; Deugnier, Y; Jouanolle, AM; Le Lan, C; Loréal, O; Troadec, MB | 1 |
6 review(s) available for deferasirox and Bronze Diabetes
| Article | Year |
|---|---|
Non-HFE hemochromatosis: pathophysiological and diagnostic aspects.
Topics: Alcohol Drinking; Benzoates; Biopsy; Cataract; Cation Transport Proteins; Decision Trees; Deferasirox; Diet; Gaucher Disease; Genetic Testing; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Inflammation; Iron; Iron Chelating Agents; Iron Metabolism Disorders; Iron Overload; Liver; Macrophage Activation Syndrome; Magnetic Resonance Imaging; Membrane Proteins; Metabolic Syndrome; Mutation; Phlebotomy; Receptors, Transferrin; Transferrin; Triazoles | 2014 |
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Siderophores; Thalassemia; Thiazoles; Triazoles | 2005 |
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone; Deferoxamine; Drug Evaluation; Drug Therapy, Combination; Forecasting; Hemochromatosis; Humans; Hydroxyethyl Starch Derivatives; Iron Chelating Agents; Iron Overload; Molecular Structure; Pyridones; Starch; Thalassemia; Thiazoles; Transfusion Reaction; Triazoles | 2006 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
Iron and the liver: update 2008.
Topics: Antimicrobial Cationic Peptides; Benzoates; Deferasirox; Hemochromatosis; Hepcidins; Homeostasis; Humans; Iron; Iron Chelating Agents; Liver; Liver Diseases; Triazoles | 2008 |
Current approach to hemochromatosis.
Topics: Antimicrobial Cationic Peptides; Benzoates; Cation Transport Proteins; Deferasirox; Hemochromatosis; Hemochromatosis Protein; Hepcidins; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Iron Overload; Membrane Proteins; Phlebotomy; Triazoles | 2008 |
1 trial(s) available for deferasirox and Bronze Diabetes
| Article | Year |
|---|---|
Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Topics: Adult; Aged; Benzoates; Biomarkers; Deferasirox; Erythrocyte Indices; Female; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Iron Overload; Male; Membrane Proteins; Middle Aged; Mutation; Time Factors; Treatment Outcome; Triazoles | 2015 |
17 other study(ies) available for deferasirox and Bronze Diabetes
| Article | Year |
|---|---|
Topics: Deferasirox; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged | 2023 |
Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Topics: Adult; Cardiomyopathies; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Extracorporeal Membrane Oxygenation; Female; Hemochromatosis; Humans; Iron Chelating Agents; Shock, Cardiogenic | 2018 |
Dose titration of deferasirox iron chelation therapy by magnetic resonance imaging for chronic iron storage disease in three adult red bald-headed uakari (Cacajao calvus rubicundus).
Topics: Animals; Benzoates; Deferasirox; Female; Hemochromatosis; Iron Chelating Agents; Male; Monkey Diseases; Pitheciidae; Triazoles | 2014 |
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged; Triazoles | 2016 |
Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.
Topics: Aged; Anti-Bacterial Agents; Benzoates; Ciprofloxacin; Deferasirox; DNA, Bacterial; Drug Therapy, Combination; Female; Hemochromatosis; Humans; Polymerase Chain Reaction; Sepsis; Triazoles; Vibrio Infections; Vibrio vulnificus | 2008 |
Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Topics: Animals; Benzoates; Deferasirox; Disease Models, Animal; Drug Evaluation, Preclinical; GPI-Linked Proteins; Hemochromatosis; Hemochromatosis Protein; Humans; Iron; Iron Chelating Agents; Magnetic Resonance Imaging; Membrane Proteins; Mice; Mice, Knockout; Organ Specificity; Triazoles | 2009 |
Deferasirox induced liver injury in haemochromatosis.
Topics: Benzoates; Chemical and Drug Induced Liver Injury; Deferasirox; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged; Triazoles | 2010 |
A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.
Topics: Adult; Aged; Amino Acid Substitution; Benzoates; Creatinine; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Hemochromatosis; Homozygote; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Phlebotomy; Safety; Transferrin; Triazoles | 2010 |
HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.
Topics: Benzoates; Brazil; Cation Transport Proteins; Combined Modality Therapy; Deferasirox; Exons; Gene Amplification; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Hypogonadism; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Membrane Proteins; Phlebotomy; Polymorphism, Single Nucleotide; Receptors, Transferrin; Stroke Volume; Triazoles; Young Adult | 2010 |
Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Benzoates; Bone Marrow Transplantation; Deferasirox; Ferritins; Hemochromatosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.
Topics: Aged; Benzoates; Chelation Therapy; Deferasirox; Female; Genotype; Hemochromatosis; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Iron Chelating Agents; Male; Membrane Proteins; Treatment Outcome; Triazoles | 2011 |
Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.
Topics: Adult; Benzoates; Deferasirox; GPI-Linked Proteins; Heart Function Tests; Hemochromatosis; Hemochromatosis Protein; Humans; Iron Chelating Agents; Liver Function Tests; Male; Triazoles | 2011 |
Deferasirox induced liver injury in haemochromatosis.
Topics: Administration, Oral; Benzoates; Chemical and Drug Induced Liver Injury; Deferasirox; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged; Triazoles | 2011 |
Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.
Topics: Anemia; Benzoates; Biomarkers; Computer Simulation; Deferasirox; Female; Ferritins; Hemochromatosis; Hemosiderin; Hepatitis C, Chronic; Humans; Iron; Iron Chelating Agents; Iron Overload; Japan; Kinetics; Liver; Male; Middle Aged; Models, Biological; Triazoles | 2012 |
The administration of deferasirox in an iron-overloaded dialysis patient.
Topics: Benzoates; Deferasirox; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Triazoles | 2013 |
[Transfusion reaction and HLA antibodies].
Topics: Acute Lung Injury; Antibody Formation; Benzoates; Blood Transfusion; Deferasirox; Hematologic Neoplasms; Hemochromatosis; HLA Antigens; Humans; Iron Chelating Agents; Isoantibodies; Myelodysplastic Syndromes; Transfusion Reaction; Triazoles | 2012 |
[Clinical findings and therapy of classical hereditary haemochromatosis (type 1)].
Topics: Benzoates; Deferasirox; Deferoxamine; Ferritins; Genes, MHC Class I; Genes, Recessive; Hemochromatosis; Humans; Phlebotomy; Point Mutation; Prognosis; Siderophores; Triazoles | 2005 |